CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.23B, above the global median of $1.15B
- FinancialsAltman Z-Score 1.24: grey zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.23BUSDvs all stocks (USD)
Revenue (TTM)
285.61MUSDvs all stocks (USD)
Profit Margin
-123.90%vs Biotechnology peers
Beta
0.6930xvs all stocks
52-Week Change
100.80%vs all stocks
Market Capitalization
2.23BUSDvs all stocks (USD)
Enterprise Value
1.97BUSDvs all stocks (USD)
Forward P/E
-15.67xvs Biotechnology peers
Price to Sales (TTM)
7.82xvs Biotechnology peers
Price to Book (MRQ)
3.04xvs Biotechnology peers
Enterprise to Revenue
6.89xvs Biotechnology peers
Enterprise to EBITDA
-6.12xvs Biotechnology peers
Gross Margin
40.50%vs Biotechnology peers
Profit Margin
-123.90%vs Biotechnology peers
Operating Margin
-113.46%vs Biotechnology peers
Return on Assets (TTM)
-23.65%vs Biotechnology peers
Return on Equity (TTM)
-47.51%vs Biotechnology peers
Revenue (TTM)
285.61MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.7490USDUpdated Jul 19, 2026Quarterly Revenue Growth
44.80%vs Biotechnology peers
Gross Profit (TTM)
112.64MUSDvs all stocks (USD)
EBITDA (TTM)
-321.62MUSDvs all stocks (USD)
Net Income (TTM)
-353.86MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
44.82%vs Biotechnology peers
Operating Cash Flow (TTM)
-270.79MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-149.07MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
263.50MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
173.18MUSDFY2025 · Dec 31, 2025Gross Profit
90.32MUSDFY2025 · Dec 31, 2025Operating Income
-398.21MUSDvs all stocks (USD)
Pre-tax Income
-393.05MUSDFY2025 · Dec 31, 2025Income Tax Expense
-2.07MUSDFY2025 · Dec 31, 2025Net Income
-390.98MUSDFY2025 · Dec 31, 2025EBIT
-398.21MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-345.75MUSDFY2025 · Dec 31, 2025Research & Development
300.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
152.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.31MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.09USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.09USDFY2025 · Dec 31, 2025Basic Shares Outstanding
357.35MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
357.35MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-390.98MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-329.03MUSDFY2025 · Dec 31, 2025Free Cash Flow
-362.87MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
169.06MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-390.98MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
47.32MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-2.07MUSDFY2025 · Dec 31, 2025Stock-based Compensation
61.58MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-13.11MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-6.66MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-25.11MUSDFY2025 · Dec 31, 2025Capital Expenditures
-33.84MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-318.67MUSDFY2025 · Dec 31, 2025Sale of Investments
400.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
47.50MUSDFY2025 · Dec 31, 2025Other Financing Charges
-7.06MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
299.25MUSDFY2025 · Dec 31, 2025Shares Outstanding
438.11MSharesUpdated Jul 19, 2026Float Shares
387.93MSharesUpdated Jul 19, 2026Shares Short
100.53MSharesUpdated Jul 19, 2026Short Ratio
7.32daysvs all stocks
Short % of Shares Outstanding
24.10%vs all stocks
% Held by Insiders
0.34%vs all stocks
% Held by Institutions
67.73%vs all stocks
Total Cash (MRQ)
313.44MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.7020USDUpdated Jul 19, 2026Total Debt (MRQ)
47.78MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0662xvs Biotechnology peers
Current Ratio (MRQ)
3.60xvs Biotechnology peers
Book Value per Share (MRQ)
1.65USDUpdated Jul 19, 2026Total Assets
913.17MUSDvs all stocks (USD)
Total Current Assets
442.69MUSDFY2025 · Dec 31, 2025Total Liabilities
214.59MUSDFY2025 · Dec 31, 2025Total Non-current Assets
470.48MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
76.23MUSDFY2025 · Dec 31, 2025Total Current Liabilities
138.36MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
163.08MUSDFY2025 · Dec 31, 2025Other Short-term Investments
133.90MUSDFY2025 · Dec 31, 2025Accounts Receivable
82.45MUSDFY2025 · Dec 31, 2025Inventory
51.68MUSDFY2025 · Dec 31, 2025Accounts Payable
22.16MUSDFY2025 · Dec 31, 2025Short-term Debt
5.04MUSDFY2025 · Dec 31, 2025Long-term Debt
44.40MUSDFY2025 · Dec 31, 2025Common Stock (Book)
17.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.78BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
698.58MUSDvs all stocks (USD)
52-Week Low
1.76USDUpdated Jul 19, 202652-Week High
5.63USDUpdated Jul 19, 202652-Week Change
100.80%vs all stocks
Beta
0.6930xvs all stocks
50-Day MA
4.03USDUpdated Jul 19, 2026200-Day MA
3.16USDUpdated Jul 19, 2026Avg 10-Day Volume
18.03MSharesUpdated Jul 19, 2026Avg 30-Day Volume
15.80MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.9200USDUpdated Jul 19, 2026Other Income / Expense
-5.14MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.41Profit Margin: -1.24
Financial Health
Altman Z-Score 1.24: grey zoneSignificant
Altman Z-Score: 1.24
Low earnings qualitySignificant
Earnings Quality Score: -0.62
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.23B, above the global median of $1.15BNotable
Market cap (USD): 2,232,511,980Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Sionna Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zai Lab Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Neogen Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Granules India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Fujian Cosunter Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule
Wedge Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Precigen Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC